Diabetic Kidney Disease

Our Approach in Managing Diabetic Kidney Disease

Every person with diabetes is at risk of kidney damage. The risk is not theoretical - it is cumulative, it is silent, and it is entirely manageable if addressed early. Our diabetic nephropathy specialist team in Mumbai, India integrates nephrology and endocrinology into a single coordinated care pathway, because treating the kidney without managing the diabetes is like bailing water without fixing the leak.

1. Annual Screening - The Non-Negotiable Starting Point

Microalbuminuria screening should begin at diagnosis for type 2 diabetes and five years after diagnosis for type 1.

• Urine albumin-to-creatinine ratio (UACR) - first morning void sample for accuracy
• UACR <30 mg/g: normal; 30–300 mg/g: microalbuminuria; >300 mg/g: macroalbuminuria
• eGFR from serum creatinine - annual monitoring once diabetes is established
• Two of three UACR measurements over 3 months positive = confirmed diabetic nephropathy
• Retinal examination - diabetic retinopathy and nephropathy track together; presence of one significantly raises probability of the other

2. Glycaemic Control - The Foundation

Poor glycaemic control is the single most important driver of kidney damage progression in diabetes.

• HbA1c target: <7% for most diabetic patients; individualised for elderly or those with hypoglycaemia risk
• Choice of glucose-lowering agents matters - SGLT2 inhibitors for kidney protection are now first-line in diabetic kidney disease independent of baseline HbA1c
• GLP-1 receptor agonists - Semaglutide, Liraglutide - provide additional renoprotective and cardiovascular benefit
• Avoid metformin at eGFR <30; dose-reduce at eGFR 30–45
• Insulin as the safest glucose-lowering agent in advanced renal impairment

3. Blood Pressure Management

Hypertension accelerates diabetic nephropathy progression more than almost any other modifiable factor.

• Target BP: <130/80 mmHg in diabetic kidney disease
• ACE inhibitor or ARB - first-line antihypertensive; reduces albuminuria in diabetes independently of BP lowering
• ACE inhibitor + ARB combination is not recommended - increases hyperkalaemia and AKI risk without additional benefit
• Finerenone - non-steroidal mineralocorticoid receptor antagonist - added on top of RAAS blockade where UACR remains elevated

4. SGLT2 Inhibitor Therapy - The Paradigm Shift

The evidence base here is unambiguous and practice-changing.

• Dapagliflozin (DAPA-CKD trial) and Empagliflozin (EMPA-KIDNEY trial) both demonstrated significant reduction in CKD progression and kidney failure events in diabetic and non-diabetic CKD
• Benefits include reduced proteinuria, reduced intraglomerular pressure, metabolic and haemodynamic renal protection
• Canagliflozin - specifically studied in diabetic nephropathy; reduces renal endpoints by approximately 30%
• SGLT2 inhibitors for kidney protection are now recommended by KDIGO guidelines as standard of care in diabetic kidney disease with eGFR ≥20

5. Lipid & Lifestyle Management

• Statin therapy - cardiovascular risk in diabetic kidney disease is high; statin use is universally recommended
• Weight management - obesity independently worsens renal haemodynamics and progression rate
• Dietary sodium restriction - <2g/day to reduce BP and fluid burden
• Smoking cessation - smoking doubles the progression rate of diabetic nephropathy; it is not optional advice
• Protein intake moderation - avoid high-protein diets; 0.8g/kg/day is appropriate in most stages

6. Monitoring Schedule & Complication Management

• UACR, eGFR, potassium, and HbA1c reviewed every 3–6 months depending on stage
• Anaemia screening as eGFR falls - ESAs and iron supplementation when indicated
• Bone mineral disease monitoring from eGFR <45
• Pre-dialysis education and vascular access planning from eGFR <20